A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse

The aim of this study was to describe real-world treatment patterns after relapsing on platform disease-modifying therapies (DMTs) in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs, as well as time to switching DMTs after relapse. Clinical effectiveness was characterized by comparing treatment failure rates in patients who escalate to high-efficacy DMTs versus those who remain on platform DMTs following initial relapse.

NCT Number	NCT07743281
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Multiple Sclerosis
Enrollment	753 participants
Start Date	2025-03-10
Primary Completion	2025-07-30 (estimated)
Study Completion	2025-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-03